Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.98 estudios en Digestive Diseases (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Rochester, Minn., Scottsdale/Phoenix, Ariz. In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy. A Study to Evaluate the Prevalence and Impact of Eating Disorders Among Patients with Inflammatory Bowel Disease Jacksonville, Fla. The purpose of this study is to assess the prevalence of eating disorders; specifically, Avoidant/Restrictive Food Intake Disorder (ARFID) among adult patients in the IBD clinic and compare to the patient population seen in the primary care clinics at Mayo Clinic Florida. A Study to Assess a New Personalized Tool for Colorectal Cancer Peritoneal Disease Treatment Rochester, Minn. The objectives of this study are to genomically characterize patient-derived organoids (PDOs) and primary tissues from colorectal peritoneal cancer (CRC) disease, to evaluate the use of PDOs as a new personalized therapy selection tool for intraperitoneal therapy in CRC peritoneal disease, and to evaluate the use of PDOs as a new personalized therapy selection tool for systemic therapy in CRC peritoneal disease. A Quality of Life Assessment of Patients with Biliary Obstruction Undergoing Endoscopic or Percutaneous Drainage Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The aim of this study is to compare the quality of life of patients with biliary obstruction who have undergone an endoscopic or percutaneous drainage. The quality of life of patients witll be assessed using the validated "European Quality of Life-5 Dimensions Questionnaire" and the "Intervention-Dependent Questionnaire" which was developed according to current literature as well as the expert opinion of gastroeneterologists. A Study to Examine Financial Distress in Patients Undergoing Treatment of Locally-advanced Rectal Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to examine the needs and gap in our understanding of financial burden experienced by rectal cancer patients from a patient perspective to help provide patient centered care and improve psychosocial outcomes of this group. A Study to Evaluate Intra-arterial Delivery of Mesenchymal Stem Cells for Luminal Ulcerative Colitis Rochester, Minn. Ulcerative Colitis (UC) is a chronic inflammatory disease affecting the mucosal lining of the colon and rectum and the incidence is increasing, but the etiology remains unknown. Patients may require a proctocolectomy due to refractory disease. Prior to an operation, UC is treated with antibiotic therapy, immunomodulatory therapy and immunosuppressive agents. While there is an increasing number of approved biologics for the treatment of UC, there are many patients that still suffer from refractory disease. Thus, alternative mechanisms of therapy are desperately needed. Treatments that have the potential to reduce mucosal inflammation could alleviate the pathology of luminal UC. This trial will use arterially delivered mesenchymal stem cells (MSCs) to produce these regenerative signals allowing for mucosal healing. This study will enroll patients with medically refractory moderate to severe inflammatory UC who are or plan to be scheduled for a colectomy. Patients enrolled will be those who failed all attempts at standard treatment including antibiotics, corticosteroids, immunomodulator, and/or biologic therapy. Participants will undergo screening for study, if eligible, participants will be dosed with 15 million or 30 million cells will be administered via IA delivery with interventional radiology. Participant study visits after study intervention includes visits on: Day 1, Week 1, Week 2, Week 8, Week 24, Week 52, and Week 104. Influence of Diet on Tissue and Body Fluids in Health and Disease Scottsdale/Phoenix, Ariz. This study aims to compare the fatty acid composition of small sample of fat (visceral and subcutaneous) removed at the time of surgery to operative outcomes and the composition calculated from the person’s dietary history and preoperative imaging with MRI/CT scans. This study will also compare the composition of pancreatic fluid collected to that of a sample of fat removed at the time of surgery to drain the collection. Furthermore, we will study the fatty acid composition of drain fluid placed at the time of surgery to that of their fat samples. The Olmsted NAFLD Epidemiology Study (TONES) Rochester, Minn. About this study Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is estimated to affect 1 in 4 adults and it is most commonly found in people who are overweight or obese. Because it is a silent disease (without symptoms until end stage) and the lab tests can be normal, it can be missed in early stages. The fat in the liver can lead to inflammation and eventually scar deposition, which can progress to cirrhosis, liver cancer and need for liver transplantation. This study aims to assess how common this disease is in Olmsted County, what markers can identify the disease early to prevent progression to cirrhosis and what other medical problems occur in people with NAFLD in addition to the liver complications. We plan to enroll a large number of adults, assess their liver with state-of-the-art tests available at Mayo Clinic and follow them over several years to monitor for disease progression and other health complications. The ultimate goal of the study is to identify new markers that predict presence of fatty liver and poor health outcomes, in order to improve population health in the community. Participation eligibility Participants will be identified from the Olmsted County population age 18 or older. Inclusion criteria: 1. Adults age 18 years or older 2. Olmsted County residents at the time of study entry Exclusion criteria: 1. Pediatric population (age<18) 2. Unwilling to participate or unable to consent 3. Known liver disease other than NAFLD at the time of survey 4. Pregnant women 5. Alcohol use in excess (14 drinks or more per week for women and 21 drinks or more per week for men) A Study to Evaluate Encorafenib Plus Cetuximab with/without Chemotherapy to Treat Metastatic Colorectal Cancer Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1 Scottsdale/Phoenix, Ariz. This study is being done to better understand the relationship between inflammation in your AT, abnormal deposition of fat around your liver and how this affects its appearance and function and ultimately insulin resistance. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 77 Ir a página 88 Ir a página 99 Ir a página 1010 SiguientePróxima página Profesionales médicos Digestive Diseases clinical-trials